In this regard, a meta-analysis showed that fatal AEs differ widely based on ICIs; while pneumonitis, hepatitis, and neurotoxic effects were the most frequent causes of death in patients receiving anti-PD-1 or anti-PD-L1, fatalities in patients receiving anti-CTLA-4 were mainly attributed to colitis. Here, CTLA4 is linked to hepatitis A virus infection.